Kallistatin level in patients with combination of chronic pancreatitis and aterosclerosis.

OBJECTIVE: Introduction: The article is devoted to the optimization of complex diagnosis in patients with combination of chronic pancreatitis and atherosclerosis. The aim: To study the level of serum kallistatin in patients with combination of chronic pancreatitis and atherosclerosis.

PATIENTS AND METHODS: Materials and methods: 89 patients with chronic pancreatitis were examined. The serum kallistatin level was determined by immunoassay using the Human Serpin A4 ELISA Kit from RayBiotech according to the application method. To determine the excretory pancreatic insufficiency all patients underwent 13C-amylase and 13C-mixed triglyceride breathing tests.

RESULTS: Results: Analysis of the study results showed that patients with less severe excretory pancreatic insufficiency and lipid profile disorders had higher kallistatin level than the control group (33.66±4.55 ng/ml). Instead, in patients with severe excretory pancreatic insufficiency and dyslipidemia, it was significantly lower - 14.69±9.21 ng/ml.

CONCLUSION: Conclusions: The interrelation between the severity of the chronic pancreatitis course with atherosclerosis and the serum kallistatin level was observed. It has been established that studies of serum kallistatin level can serve as a marker of the chronic pancreatitis` severity in combination with atherosclerosis.